Tags |
|
|
Links |
|
|
Main Subject - List Building for Experts - How to Increase Your Email Open Rate III
On that note, I realize that if you are getting 100s of daily em
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
ails from subscribers, you get to the point you can no longer of
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
er that personal service. At the time of this writing, I have a
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
out 6000 active subscribers who spend over $11,000 per month wit
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
h me, and I find I can answer all my email in about ? an hour a
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
ay. As my list grows, and the time it takes me to answer emails
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
personally goes up, I will inevitably be forced to go to a ticke
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
t system. But I encourage you to answer emails personally as lo
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
g as you can reasonably do it.
Another thing I like to do, espe
Another thing I like to do, espe
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
ially if I send out an ‘I need your help’ email to my entire lis
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
, is to answer the emails in a group email. I find that many of
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
the questions people ask will pertain to many others on my list
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
so I will simply reprint the questions, and answer several ques
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
ions at one time, and send that email to my entire list.
I thin
I thin
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
k that this creates a feeling of community. Even those who have
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
not asked me questions can feel as though they are involved in t
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
is conversation. They can feel included, and they will feel as
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
though I have a responsive list – one that interacts with me – s
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
why shouldn’t they?
You have to do whatever it takes to improv
You have to do whatever it takes to improv
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
your response rates – and you have to test and track to do that
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.mainsubjects.org.ua/article/71290/mainsubjects-List-Building-for-Experts--How-to-Increase-Your-Email-Open-Rate-III.html">List Building for Experts - How to Increase Your Email Open Rate III</a>
BB link (for phorums):
[url=http://www.mainsubjects.org.ua/article/71290/mainsubjects-List-Building-for-Experts--How-to-Increase-Your-Email-Open-Rate-III.html]List Building for Experts - How to Increase Your Email Open Rate III[/url]
Related Articles:
Networking Skills: How to be Winsome
10 Expressions to Avoid in Sales Communication
Bookmark it:
|